Vous n'êtes pas identifié (connexion)

Centre de recherche

VENDREDI 15 DÉC

Calendrier >

CARRIÈRES

Liste des opportunités >

BOTTIN

Éric Lévesque

Formation
à venir

Aucune offre active

Autres opportunités de carrière
Axe principal
Endocrinologie et néphrologie
Adresse(s)
Centre Hospitalier de l'Université Laval (CHUL)
2705, boulevard Laurier
R-4720
Québec (Québec)
CANADA G1V 4G2

Centre Hospitalier de l'Université Laval (CHUL)
2705, boulevard Laurier
R-4701.9
Québec (Québec)
CANADA G1V 4G2

Téléphone(s)
+1 418-525-4444, poste 42296 / +1 418-525-4444, poste 46454
Télécopieur(s)
+1 418-654-2298
Courriel(s)
Eric.Levesque@crchudequebec.ulaval.ca

Publications récentes (voir toutes les publications de ce chercheur)

Labriet A, De Mattia E, Cecchin E, Levesque E, Jonker D, Couture F, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G, Guillemette C. Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. Frontiers in pharmacology,  2017. 8: 712
Beland S, Vallin P, Desy O, Levesque E, De Serres SA. Effects of alloantibodies to human leukocyte antigen on endothelial expression and serum levels of thrombomodulin. Journal of thrombosis and haemostasis : JTH,  2017. 15: 1020-1031
Cornu JN, Audet-Walsh E, Drouin S, Bigot P, Valeri A, Fournier G, Azzouzi AR, Roupret M, Cormier L, Chanock S, Guillemette C, Cussenot O, Levesque E, Cancel-Tassin G. Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway. World journal of urology,  2017. 35: 293-298
Lacombe L, Fradet V, Levesque E, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C. Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. Cancer prevention research (Philadelphia, Pa.),  2016. 9: 189-95
Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Levesque E, Droit A, Guillemette C. Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. The pharmacogenomics journal,  2016. 16: 60-70
Margaillan G, Levesque E, Guillemette C. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. The Journal of steroid biochemistry and molecular biology,  2016. 155: 85-93
Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Tetu B, Fradet Y, Lacombe L, Guillemette C, Levesque E. The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. European urology,  2016. 69: 601-9
Saad F, Winquist E, Hubay S, Berry S, Assi H, Levesque E, Aucoin N, Czaykowski P, Lattouf JB, Alloul K, Stewart J, Sridhar SS. Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. Canadian Urological Association journal = Journal de l’Association des urologues du Canada.,  2016. 10: 102-9
Laverdiere I, Flageole C, Audet-Walsh E, Caron P, Fradet Y, Lacombe L, Levesque E, Guillemette C. The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. Endocrine-related cancer,  2015. 22: 77-85
Chen S, Laverdiere I, Tourancheau A, Jonker D, Couture F, Cecchin E, Villeneuve L, Harvey M, Court MH, Innocenti F, Toffoli G, Levesque E, Guillemette C. A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. The pharmacogenomics journal,  2015. 15: 513-20
© 2017 Tous droits réservés Centre de recherche du CHU de Québec